Rani Therapeutics Q2 2026 net loss $8.4M; RT-114 oral bioavailability >150% vs subcutaneous

Rani Therapeutics Holdings, Inc.

RT-114 Phase 1a: oral bioavailability >150% vs matched subcutaneous PG-102; no serious adverse events.
First participants dosed in Phase 1a expansion cohort; Phase 1b in obesity expected by end 2026.
Completed $20M registered direct offering; cash $53.4M as of June 30, 2026, sufficient through 2027.
New PegBio collaboration to explore oral delivery of obesity/metabolic molecules via RaniPill.
Appointed Nicholas Maestas as CFO and Michelle Gilson to Board; net loss $8.4M vs $11.2M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.